Would you give immunotherapy to patient with metastatic NSCLC who had liver transplant for hepatocellular carcinoma and now is progressing on chemotherapy?

This highly challenging question addresses a very important general issue in the context of a unique patient case. How far can we push the boundaries of using checkpoint inhibitors in understudied patient populations at significantly increased risk from adverse events? Or in different words, how muc...